Dr. Samuel Nordberg discusses methods for identifying patients in need of an alternative therapy for TRD at the health system level.

Samuel Nordberg, PhD, discusses challenges with the definition and identification of TRD in the clinical setting.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

Neither party wants to be perceived as threatening Medicare. The Biden administration has taken steps to reduce payment to ...

After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...

The patient panels of physicians underrepresented in medicine (URiM) showed that they had greater odds of being a Medicaid ...

Novo Nordisk said it’s open to discussions with PBMs based on their commitments that a lower semgalutide list price would not ...

A study found omitting a course of antibiotic prophylaxis was non-inferior to the routinely administering antibiotics in ...

Employment satisfaction, sleep quality and lack of physical movement were all tied to vitality levels, survey results show.

The Phase I/II trials for rare forms of hereditary blindness further confirmed the potential for gene therapy treatments of ...

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually.

Gilead Sciences is issuing a voluntary recall of one lot of Veklury (remdesivir) for Injection 100 mg/vial because of glass ...